Cited by 269Gout, Hyperuricemia, Uric AcidDrug-Induced Adverse ReactionsBiochemical and Molecular Research

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout

Open access

BECKER, MICHAEL A., SCHUMACHER, H. RALPH, MacDONALD, PATRICIA A., LLOYD, ERIC, LADEMACHER, CHRISTOPHER·2009·The Journal of Rheumatology

DOI 10.3899/jrheum.080814

Open this paper in CoChat — free account Open PDF

Abstract

Objective.: To determine longterm urate-lowering efficacy and clinical benefits and safety of therapy with febuxostat or allopurinol in subjects with gout. Methods.: Subjects (n = 1086) in this open-label extension study were assigned to fixed-dose daily urate-lowering treatment (ULT) with febuxostat (80 mg or 120 mg) or allopurinol (300 mg). ULT reassignment was permitted during months 1 to 6 to achieve serum urate (SUA) concentrations between 3.0 and < 6.0 mg/dl. Flares requiring treatment, tophus size, safety, and SUA levels were monitored during up to 40 months of ULT maintenance. Results.: After 1 month initial treatment, > 80% of subjects receiving either febuxostat dose, but only 46% of subjects receiving allopurinol, achieved SUA < 6.0 mg/dl. After ULT reassignment, > 80% of all remaining subjects maintained the primary efficacy endpoint of SUA < 6.0 mg/dl at each visit. More subjects initially randomized to allopurinol required ULT reassignment to achieve SUA < 6.0 mg/dl compared with subjects receiving febuxostat. Maintenance of SUA < 6.0 mg/dl resulted in progressive reduction to nearly 0 in proportion of subjects requiring gout flare treatment. Baseline tophus resolution was achieved by 46%, 36%, and 29% of subjects maintained on febuxostat 80 mg, febuxostat 120 mg, and allopurinol, respectively. Overall adverse event rates (including cardiovascular adverse event rates), adjusted for 10-fold greater febuxostat than allopurinol exposure, did not differ significantly among treatment groups. Conclusion.: Durable maintenance of goal range SUA level with either dose of febuxostat or in smaller numbers of subjects with allopurinol resulted in near elimination of gout flares and improved tophus status over time. Registered as NCT00175019.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3899/jrheum.080814

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., McCarty, D. J., & Yű, T.-F. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,433
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V., Conaghan, P. G., Gerster, J., Jacobs, J. W. G., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,406
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Self-citation
Severe allopurinol toxicity
Hande, K. R., Noone, R. M., & Stone, W. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90743-5 · Cited by 679
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Self-citation
Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout
Pérez-Ruiz, F., Calabozo, M., Pijoán, J. I., Herrero-Beites, A. M., & Ruibal, A. (2002) · Arthritis Care & Research · doi:10.1002/art.10511 · Cited by 455
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy
Shoji, A., Yamanaka, H., & Kamatani, N. (2004) · Arthritis Care & Research · doi:10.1002/art.20405 · Cited by 439
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
Takano, Y., Hase-Aoki, K., Horiuchi, H., Zhao, L., Kasahara, Y., Kondo, S., & Becker, M. A. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.031 · Cited by 339
Self-citation
Gout Medication Treatment Patterns and Adherence to Standards of Care From a Managed Care Perspective
Sarawate, C. A., Brewer, K., Yang, W., Patel, P., Schumacher, H. R., Saag, K. G., & Bakst, A. W. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.925 · Cited by 293
Self-citation
Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout
Pérez-Ruiz, F., Alonso-Ruiz, A., Calabozo, M., Herrero-Beites, A. M., Erauzkin, G. G., & Ruiz-Lucea, E. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.9.545 · Cited by 258

Show all 23 references

Sorted by citations

Items 101–200 of 269

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
Dalbeth, N., Jones, G., Terkeltaub, R. A., Khanna, D., Fung, M. M., Baumgartner, S., & Pérez-Ruiz, F. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1788-4 · Cited by 27
Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials
Singh, A., Singh, K., Sharma, A., Kaur, K., Chadha, R., & Bedi, P. M. S. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00316g · Cited by 28
Allopurinol: insights from studies of dose–response relationships
Day, R. O., Kannangara, D. R. W., STOCKER, S. L., Carland, J. E., Williams, K. M., & Graham, G. G. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1269745 · Cited by 27
Use of febuxostat in the management of gout in the United Kingdom
Waller, A., & Jordan, K. M. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16682010 · Cited by 27
Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
Pillinger, M. H. (2010) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s5563 · Cited by 25
Multicenter, Open-Label Study of Long-Term Administration of Febuxostat (TMX-67) in Japanese Patients With Hyperuricemia Including Gout
Kamatani, N., Fujimori, S., Hada, T., Hosoya, T., Kohri, K., Nakamura, T., Ueda, T., Yamamoto, T., Yamanaka, H., & Matsuzawa, Y. (2011) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31822541d0 · Cited by 25
Plasmodium falciparum-Derived Uric Acid Precipitates Induce Maturation of Dendritic Cells
van de Hoef, D. L., Coppens, I., Holowka, T., Mamoun, C. B., Branch, O. H., & Rodrı́guez, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055584 · Cited by 25
Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities
Dalbeth, N., McQueen, F. M., Singh, J. A., MacDONALD, P. A., Edwards, N. L., Schumacher, H. R., Simon, L. S., Stamp, L. K., Neogi, T., Gaffo, A., et al. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110272 · Cited by 24
Self-citation
Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure
Singh, J. A., & Yu, S. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209046 · Cited by 24
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis
Wang, M., Zhang, Y., Zhang, M., Li, H., Wen, C., Zhao, T., Xie, Z., & Sun, J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1564 · Cited by 24
Protein phosphatase 2A regulates xanthine oxidase-derived ROS production in macrophages and influx of inflammatory monocytes in a murine gout model
Elsayed, S., & Elsaid, K. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1033520 · Cited by 24
Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
Singh, J. A. (2016) · BMC Medicine · doi:10.1186/s12916-016-0732-1 · Cited by 26
Evaluation and Treatment of Gout as a Chronic Disease
Pérez-Ruiz, F., & Herrero-Beites, A. M. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0059-z · Cited by 23
The association between urate‐lowering therapies and treatment‐related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta‐analysis of randomized trials
Zhang, S., Xie, Q., Xie, S., Chen, J., Deng, Q., Zhong, L., Guo, J., & Yu, Y. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2609 · Cited by 24
Timing of intra-lesion shaving for surgical treatment of chronic tophus
Lee, S., Chen, M.-C., Chou, Y.-H., Lin, S., Lai, C., & Chen, Y.-C. (2013) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2013.03.041 · Cited by 23
Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat
Hatoum, H. T., Khanna, D., Lin, S., Akhras, K. S., Shiozawa, A., & Khanna, P. P. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.03.2741 · Cited by 27
Practical application of national clinical guidelines for the management of gout (preliminary data)
Chikina, M. N., Елисеев, М. С., & Zhelyabina, O. V. (2020) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2020-2-97-103 · Cited by 22
The role of dual energy computed tomography in the differentiation of acute gout flares and acute calcium pyrophosphate crystal arthritis
Kravchenko, D., Karakostas, P., Kuetting, D. L. R., Meyer, C., Brossart, P., Behning, C., & Schäfer, V. S. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05949-4 · Cited by 22
The Italian Society of Rheumatology clinical practice guidelines for the diagnosis and management of gout
Ughi, N., Prevete, I., Ramonda, R., Cavagna, L., Filippou, G., MANARA, M., Bortoluzzi, A., Parisi, S., Ariani, A., & Scirè, C. A. (2019) · Reumatismo · doi:10.4081/reumatismo.2019.1176 · Cited by 21
Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
Stamp, L. K., Khanna, P. P., Dalbeth, N., Boers, M., Maksymowych, W. P., Schumacher, H. R., Becker, M. A., MacDONALD, P. A., Edwards, N. L., Singh, J. A., et al. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110273 · Cited by 21
Self-citation
Dual‐energy computed tomography for monitoring the effect of urate‐lowering therapy in gouty arthritis
Sun, Y., Chen, H., Zhang, Z., Ma, L., Zhou, J., Zhou, Y., Ding, Y., Jin, X., & Jiang, L. (2015) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12634 · Cited by 21
How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials
Stewart, S., Tallon, A., Taylor, W. J., Gaffo, A., & Dalbeth, N. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.11.002 · Cited by 20
Urate Crystal Deposition Disease and Gout—New Therapies for an Old Problem
Girardet, J., & Miner, J. N. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00011-0 · Cited by 21
Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649
Dua, P., Gurrell, R., Kirby, S., Sudworth, M., & Loudon, P. T. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3273-2 · Cited by 20
Risk of Febuxostat-Associated Myopathy in Patients with CKD
Liu, C.-T., Chen, C., Hsu, C., Huang, P., Lin, F., Chen, J., & Lin, S. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08280816 · Cited by 19
Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials
Xie, H., Hu, N., Pan, T. S., Wu, J.-C., Yu, M., & Wang, D. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00723-5 · Cited by 24
Long-Term Management of Gout
Chaichian, Y., Chohan, S., & Becker, M. A. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.01.012 · Cited by 20
Self-citation
Interventions for tophi in gout
Sriranganathan, M. K., Vinik, O., Bombardier, C., & Edwards, C. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010069.pub2 · Cited by 19
Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements
Stamp, L. K., Morillon, M. B., Taylor, W. J., Dalbeth, N., Singh, J. A., Lassere, M. N., & Christensen, R. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.170911 · Cited by 19
Portuguese recommendations for the diagnosis and management of gout.
Araújo, F., Cordeiro, I. M., Teixeira, F., Rovisco, J., Ramiro, S., Mourão, A. F., Costa, J. A., Pimentão, J. B., Malcata, A., Santos, M. J., et al. (2014) · PubMed · Cited by 18
Recent pharmacological advances in the management of gout
Davies, K., & Bukhari, M. A. S. (2017) · Rheumatology · doi:10.1093/rheumatology/kex343 · Cited by 18
A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
Zhang, F., Liu, Z., Jiang, L., Zhang, H., Zhao, D., Li, Y., Zou, H., Wang, X., Li, X.-P., Shi, B., et al. (2019) · Rheumatology and Therapy · doi:10.1007/s40744-019-00173-8 · Cited by 17
Österreichische 3e-Empfehlungen zu Diagnose und Management von Gicht 2013
Sautner, J., Gruber, J., Herold, M., Zwerina, J., & Leeb, B. F. (2013) · Wiener klinische Wochenschrift · doi:10.1007/s00508-013-0469-1 · Cited by 18
SAT0519 Facilitators and Barriers to Adherence to Urate-Lowering Therapy in African-Americans with Gout: A Qualitative Study
Singh, J. A. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-eular.1148 · Cited by 18
Interventions for Tophi in Gout: A Cochrane Systematic Literature Review
Sriranganathan, M. K., Vinik, O., Falzon, L., Bombardier, C., van der Heijde, D. M. F. M., & Edwards, C. J. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140464 · Cited by 17
Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort
Singh, J. A., Yang, S., & Saag, K. G. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190522 · Cited by 17
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model
Hill‐McManus, D., Marshall, S. F., Soto, E., Lane, S., & Hughes, D. A. (2018) · Value in Health · doi:10.1016/j.jval.2018.06.002 · Cited by 16
Identification of Gout Flares in Chief Complaint Text Using Natural Language Processing.
Osborne, J. D., Booth, J. S., O’Leary, T., Mudano, A. S., Rosas, G., Foster, P. J., Saag, K. G., & Danila, M. I. (2020) · PubMed Central · Cited by 16
Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection
Kamel, B., Williams, K. M., Graham, G. G., Norris, R. L. G., STOCKER, S. L., Carland, J. E., Pile, K. D., & Day, R. O. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.121764 · Cited by 16
Allopurinol adherence and its predictors in gout: a national cohort study in US veterans
Singh, J. A., Richman, J., Yang, S., Bridges, S., & Saag, K. G. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30029-1 · Cited by 16
Effects of Febuxostat on Mortality and Cardiovascular Outcomes
Al‐Abdouh, A., Khan, S. U., Barbarawi, M., Upadhrasta, S., Munira, S., Bizanti, A., Elias, H., Jat, A., Zhao, D., & Michos, E. D. (2020) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.04.012 · Cited by 16
Gout measures: Gout Assessment Questionnaire (GAQ, GAQ2.0), and physical measurement of tophi
Taylor, W. J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20622 · Cited by 16
Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach
Yoshida, K., Liu, J., Desai, R. J., Glynn, R. J., Solomon, D. H., & Kim, S. C. (2023) · Epidemiology · doi:10.1097/ede.0000000000001608 · Cited by 16
Management of complex gout in clinical practice: Update on therapeutic approaches
Narang, R. K., & Dalbeth, N. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.010 · Cited by 15
Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial
Jia, E., Zhang, Y., Ma, W., Li, B., Geng, H., Zhong, L., Yao, X., Xie, J., Xiao, Y., Jiang, Y., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa908 · Cited by 14
Febuxostat for the treatment of gout
Bridgeman, M. B., & Chavez, B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.985588 · Cited by 14
Urate-Lowering Therapy for the Management of Gout: A Summary of 2 Cochrane Reviews
Kydd, A. S., Seth, R., Buchbinder, R., Falzon, L., Edwards, C. J., van der Heijde, D. M. F. M., & Bombardier, C. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140460 · Cited by 15
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore
Pruis, S.-L., Jeon, Y. K., Pearce, F., Thong, B. Y., & Aziz, M. I. A. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1757456 · Cited by 15
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis
Barrientos-Regala, M. A., Macabeo, R., Ramirez-Ragasa, R., Pestaño, N. S., Punzalan, F. E. R., Tumanan-Mendoza, B. A., & Castillo, R. R. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000871 · Cited by 15
Allopurinol to Febuxostat: How far have we come?
Stockert, A., & Stechschulte, M. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6286 · Cited by 14
Current and Future Therapeutic Options for the Management of Gout
Whelton, A. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181df8ad2 · Cited by 14
Revisão crítica do tratamento medicamentoso da gota no Brasil
Azevedo, V. F., Lopes, M. P., Catolino, N. M., Paiva, E. D. S., Araújo, V. A., & Pinheiro, G. D. R. C. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2016.06.009 · Cited by 13
Cardiovascular safety of febuxostat. Analysis of the CARES study
Елисеев, М. С. (2018) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2018-4-42-46 · Cited by 13
Clinical Features and Treatment of Gout
Burns, C. M., & Wortmann, R. L. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00095-5 · Cited by 12
Patient Perceptions of Gout Management Goals
Singh, J. A., & Edwards, N. L. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000981 · Cited by 13
Adherence to uric acid treatment guidelines in a rheumatology clinic
Conway, R. P., Coughlan, R. J., & CAREY, J. J. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-2081-6 · Cited by 12
Burden and management of gout in a multi-ethnic Asian cohort
Chua, C. K. T., Cheung, P., Santosa, A., Lim, A. Y. N., & Teng, G. G. (2019) · Rheumatology International · doi:10.1007/s00296-019-04475-6 · Cited by 12
Advances in gout: some answers, more questions
Singh, J. A. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3110 · Cited by 11
Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study
Yang, T., Leu, H., Lin, S.-J., Horng, J., & Shih, C.-M. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.05.040 · Cited by 12
Computational biomedical modeling and screening for prediction of molecular mechanisms of Simiao Pill against hyperuricemia
Chen, Q., Chen, X., Chen, X., Li, M., Komori, A., Sun, X., Liu, Y., Hung, A., Hung, A., Zhao, X., et al. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121827 · Cited by 11
Gout tophus on an intradural fascicle: a case description
Willner, N., Monoranu, C., Stetter, C., Ernestus, R., & Westermaier, T. (2015) · European Spine Journal · doi:10.1007/s00586-015-4309-z · Cited by 11
Cost-effectiveness analysis of febuxostat in patients with gout in Spain
Pérez-Ruiz, F., Díaz‐Torné, C., & Carcedo, D. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1149482 · Cited by 11
What Is the Evidence for Treat-to-Target Serum Urate in Gout?
Bursill, D., & Dalbeth, N. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0719-3 · Cited by 12
Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
Jutkowitz, E., Alarid‐Escudero, F., Choi, H. K., Kuntz, K. M., & Jalal, H. J. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0526-0 · Cited by 11
Major unanswered questions in the clinical gout field
Stamp, L. K. (2016) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000367 · Cited by 9
Critical revision of the medical treatment of gout in Brazil
Azevedo, V. F., Lopes, M. P., Catolino, N. M., Paiva, E. D. S., Araújo, V. A., & Pinheiro, G. D. R. C. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.03.002 · Cited by 10
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
Dewi, C., Puspita, F., Puspitasari, I. M., & Zakiyah, N. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s424598 · Cited by 11
Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials
Deng, H., Zhang, B. L., Tong, J. D., Yang, X. H., & Jin, H. M. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200307 · Cited by 10
Hyperuricemia and gout: effects on bone and articular cartilage (literature review)
Черемушкина, Е. В., & Елисеев, М. С. (2022) · Obesity and metabolism · doi:10.14341/omet12894 · Cited by 9
Patient considerations in the management of gout and role of combination treatment with lesinurad
Claus, L. W., & Saseen, J. J. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s108868 · Cited by 9
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients
Presa, M., Pérez-Ruiz, F., & Oyagüez, I. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04739-3 · Cited by 9
Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study
Shen, M., Zhang, J., Qian, K., Li, C., Xu, W., Gu, B., Wang, X., Ren, Q., Yang, L., Yuan, H. D., et al. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4283-z · Cited by 8
Hyperuricemia in Patients With Coronary Artery Disease and Its Association With Disease Severity
Padda, J., Khalid, K., Almanie, A. H., Hennawi, H. A., Mehta, K. A., Fernando, R. W., Padda, S., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.17161 · Cited by 8
Chasing crystals out of the body: will treat to serum urate target for gout help us get there?
Singh, J. A., & Uhlig, T. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210436 · Cited by 8
Pharmacodynamic Monitoring Using Biomarkers to Individualize Pharmacotherapy
Theile, D., & Cho, W. C. S. (2019) · Biomarkers in Medicine · doi:10.2217/bmm-2018-0355 · Cited by 7
Impact of urate-lowering therapy on quality of life indicators in patients with gout
Chikina, M. N., Zhelyabina, O. V., & Елисеев, М. С. (2021) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2021-3-62-68 · Cited by 7
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout
Graham, G. G., STOCKER, S. L., Kannangara, D. R. W., & Day, R. O. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0760-2 · Cited by 7
Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice
Singh, J. A., Richards, J. S., Chang, E., Toupin‐April, K., & Barton, J. L. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05421-9 · Cited by 6
The effect of initiation of urate-lowering treatment during a gout flare on the current episode: a meta-analysis of randomized controlled trials
Jia, E., Yao, X., Geng, H., Zhong, L., Xie, J., Xiao, Y., Jiang, Y., Qiu, X., Xiao, M., Zhang, Y., et al. (2022) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-022-00236-5 · Cited by 6
Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
Kamel, B., Abuhelwa, A. Y., Foster, D. J. R., Duong, J. K., Graham, G. G., Williams, K. M., Pile, K. D., & Day, R. O. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15462 · Cited by 5
Kristallinduzierte Inflammasomaktivierung: Gicht und Pseudogicht
Winzer, M., Tausche, A. K., & Aringer, M. (2009) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-009-0489-4 · Cited by 6
Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout
Hill‐McManus, D., Marshall, S. F., Soto, E., & Hughes, D. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1454 · Cited by 9
Gout, hyperuricemia and chronic kidney disease: New treatment possibilities
Kochman, P., & Stompór, T. P. (2016) · Polish Annals of Medicine · doi:10.1016/j.poamed.2016.04.001 · Cited by 6
A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients
Pichholiya, M., Yadav, A. K., Luhadia, S. K., Tahashildar, J., & Aseri, M. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.190729 · Cited by 7
Improving adherence to urate‐lowering therapy in people living with gout
Coleshill, M. J., Aung, E., Nguyen, A., STOCKER, S. L., Baysari, M. T., Kamel, B., Schulz, M., McLachlan, A. J., & Day, R. O. (2019) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13566 · Cited by 5
Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia
Ghossan, R., Tabesh, O. A., Fayad, F., Richette, P., & Bardin, T. (2023) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000002045 · Cited by 6
Can racial disparities in optimal gout treatment be reduced? evidence from a randomized trial
Singh, J. A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-15 · Cited by 5
Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?
Coleshill, M. J., Aung, E., Carland, J. E., Faasse, K., STOCKER, S. L., & Day, R. O. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00198-0 · Cited by 5
Surgical Treatment of a Young Patient with Bilaterally Destroyed First Metatarsophalangeal Joints Suffering from Gout
Wünschel, M., Wülker, N., & Walter, C. (2012) · Journal of the American Podiatric Medical Association · doi:10.7547/1020334 · Cited by 4
Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis
Yan, Y., Bai, Y., Wang, J., & Li, G. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430304 · Cited by 4
Febuxostat for the treatment of hyperuricemia in patients with gout
Kelly, V., & Krishnan, E. (2011) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.11.46 · Cited by 4
Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients
Weng, S., Tarng, D., Chen, Y., Wu, M., & on behalf of the CKDBHPDH investigators (2016) · Cogent Medicine · doi:10.1080/2331205x.2016.1213215 · Cited by 5
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout
Lertnawapan, R., & Jatuworapruk, K. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05262-6 · Cited by 4
Xanthine Oxidase Inhibitor Treatment of Hyperuricemia
Dalbeth, N., & Stamp, L. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2864-4.10013-2 · Cited by 4
Crystal Arthropathies: Recognizing and Treating “The Gouch”
Quillen, D. M. (2010) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2010.07.008 · Cited by 4
Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective
Klein, R. W., Kabadi, S., Cinfio, F. N., Bly, C. A., Taylor, D. C. A., & Szymanski, K. A. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0103 · Cited by 4
What is the Best Choice for Urate-lowering Therapy for Korean?
Cheon, Y., & Song, J. S. (2020) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2020.27.2.78 · Cited by 4
In vitro and In silico Xanthine Oxidase Inhibitory Activities of 3-Aryl-2- thioxo-2,3-dihydroquinazolin-4(1H)-one Derivatives
Gul, A., Saad, S. M., Zafar, H., Wahab, A., Khan, K. M., & Choudhary, M. I. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220620124034 · Cited by 3
The efficacy and safety of different doses of febuxostat and allopurinol: A meta-analysis
Zhang, F., & Wang, Y. (2025) · Joint Diseases and Related Surgery · doi:10.52312/jdrs.2025.1976 · Cited by 3
Combination of dual-energy CT findings and clinical features predicts risk of frequent flares of gout
Yu, W., Wang, K., Liu, J., Chen, M., Yang, Z., Li, C., Han, L., Chen, Y., Nie, P., & Xu, W. (2025) · European Radiology · doi:10.1007/s00330-025-12108-9 · Cited by 3

Authors: BECKER, M. A., SCHUMACHER, H. R., MacDONALD, P. A., LLOYD, E., & LADEMACHER, C.
Affiliations: University of Chicago (US)
University of Pennsylvania (US)
Takeda (Japan) (JP)
ORCID: BECKER, MICHAEL A.
Venue: The Journal of Rheumatology
Publisher: The Journal of Rheumatology
Published: 2009-03-13
Volume: 36
Issue: 6
Pages: 1273-1282
ISSN: 0315-162X (ISSN-L)
1499-2752
DOI: 10.3899/jrheum.080814
OpenAlex: W2145066076
Cited by: 269
References: 23
Citations by year: 2026: 2 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 10 · 2020: 21 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 15 · 2014: 24 · 2013: 20 · 2012: 15
FWCI: 12.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The Journal of Rheumatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords: gout, febuxostat, allopurinol, urate-lowering therapy, serum uric acid, gout flares, long-term maintenance therapy, cardiovascular adverse events, drug safety
MeSH terms: Febuxostat, Allopurinol, Gout, Gout Suppressants, Thiazoles, Uric Acid, Treatment Outcome, Hyperuricemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks